PayerDiabetes Drug's New Weight Loss Formula Fuels Cost-Benefit Debate
It's no surprise that some of the same drugs for diabetes are being reformulated and renamed by manufacturers as a...
PayerPfizer Court Fight Could Legalize Medicare Copays and Unleash 'Gold Rush' in Sales
A Pfizer win could cost taxpayers billions of dollars and erase an important control on pharma marketing after decades of...
InnovationAnalytics and Hospital Pharmacies: Building a Successful Program
The requests received for data became more complex, requiring some to move away from just patient use data and incorporate...
StrategyBiden's July Executive Order Includes Drug Pricing Provisions. But Will They Do Enough?
So far, experts generally say the jury is still out on how meaningful these efforts will be.
Clinical CareMedication Non-Adherence: Solving an Eternal Challenge
Healthcare plans for the underserved markets, which include patients using Medicaid, Medicare Dual Advantage, or a healthcare exchange, offer limited...
StrategyAHA, 340B Health Applaud SCOTUS Decision to Hear Medicare Cuts Case
The AHA applauded the Supreme Court's announcement in a statement released Friday morning.
Clinical CareHow One Rural Town Without a Pharmacy Is Crowdsourcing to Get Meds
Walden, Colorado has suffered the fate of many small towns across the United States, as the economics of the pharmacy...
StrategyStates Step Up Push to Regulate Pharmacy Drug Brokers
The companies are powerful, together administering medication plans for more than 266 million Americans.
PayerChange to Gilead Assistance Program Threatens PrEP Access, HIV Advocates Say
The Advancing Access program offers free medicine to the uninsured.
InnovationFDA Weighs Approval of a Lucrative Alzheimer's Drug, but Benefits Are Iffy
The agency said it will decide by June 7 the fate of Biogen's drug aducanumab.
StrategyPodcast: KHN's 'What the Health?': Drug Price Effort Hits a Snag
Concerns raised by a group of moderate Democrats threaten to derail a bill being pushed by House Democratic leaders.
Covid-19Scientists Seek COVID Treatment Answers in Cheap, Older Drugs
A $10, two-week course of fluvoxamine could reduce death and hospitalizations.